This is an easy-to-read manual about chelation therapy. It contains specific protocols for the treatment of chronic metal overexposure, all of which are evidence-based, aiding the inexperienced and the experienced therapist in selecting the optimal chelating agent for the metal(s) in question. Expert chemists and chelation therapists have contributed invaluable knowledge and experience to this book. Most importantly, this is not a book promoting personal views or preferences. In fact, the information presents and explains different approaches, and allows the reader to draw his own conclusion. All the protocols listed have been modified for the treatment of chronic metal intoxication, included are oral and intravenous treatment plans. The authors explain in simple terms how a chelating agent ́s bioavailability affects metal binding and how various protocols such as the Cutler Protocol affect the detoxification process, why DMPS binds mercury and which chelators are useful for the detoxification of certain organ system. Also discussed is the importance and effect of treatment pauses. Diagnostic tests are discussed, and which are useful under certain conditions. Shown are tables comparing the average metal binding ability of the various EDTAs, DMPS, DMSA and other chelating agents. Detailed information explains which chelator binds which metal and why, all of which aids the therapist in finding optimal treatment schedules. Novel chelating agents are presented such as MIADMSA, a new oral chelator specifically designed for arsenic intoxication, or how natural Pectin may be used an alternative for gadolinium intoxication, which metals are bound by lipoic acid and why a slightly alkaline environment supports metal binding, even preventing the often-feared metal redistribution. All in all, this evidence-based chelation "cookbook" should be in medical libraries and on the bookshelf of every physician treating environmental disease.

Chelation therapy, based on the intravenous infusion of EDTA, is a highly effective treatment for atherosclerotic cardiovasular disease. Saftey and effectivenss are well documented in clinical studies, all of which to date are supportive of this therapy, and there are no studies showing lack of effectiveness. A strong case is made for the use of this safe, efficacious, and inexpensive therapy before resorting to surgery and other risky and invasive treatments. In this newly revised and extensively updated edition of what has come to be regarded as the definitive textbook on the subject, renowned chelation expert Elmer M. Cranton, M.D., presents the work of the world's leading experts in chelation therapy. "This therapy has been proven effective over and over again in clinical practice," says Dr. Cranton. "More than one million patients have recieved more than twenty million infusions with no serious or lasting adverse effects." In his foreword, Nobel Prize winner Dr. Linus Pauling states, "EDTA chelation therapy makes good sense to me as a chemist and medical researcher. It has a rational scientific basis, and the evidence for clinical benefit seems to be quite strong." Here in a single volume you will learn everything you need to know to responsibly administer and advocate chelation therapy. You will find a coherent scientific rationale, clinical trials demonstating effectiveness, guidelines for saftey, detailed protocols for administration, and techniques for pre- and post-treatment laboratory evalutaion.

Chelation Therapy in the Treatment of Metal Intoxication presents a practical guide to the use of chelation therapy, from its basic chemistry, to available chelating antidotes, and the application of chelating agents. Several metals have long been known to be toxic to humans, and continue to pose great difficulty to treat. These challenges pose particular problems in industrial settings, with lead smelting known to be associated with hemopoietic alterations and paralyses, and the inhalation of mercury vapor in mercury mining being extremely detrimental to the central nervous system. Clinical experience has demonstrated that acute and chronic human intoxications with a range of metals can be treated efficiently by administration of chelating agents. Chelation Therapy in the Treatment of Metal Intoxication describes the chemical and biological principles of chelation in the treatment of these toxic metal compounds, including new chelators such as meso-2,3-dimercaptosuccinic acid (DMSA) and D,L-2,3-dimercapto-1-propanesulfonic acid (DMPS). Presents all the current findings on the potential for chelation as a therapy for metal intoxication Presents practical guidelines for selecting the most appropriate chelating agent Includes coverage on radionuclide exposure and metal storage diseases Describes the chemical and biological principles of chelation in the treatment of toxic metal compounds

Within the last few years, iron research has yielded exciting new insights into the under standing of normal iron homeostasis. However, normal iron physiology offers little protec tion from the toxic effects of pathological iron accumulation, because nature did not equip us with effective mechanisms of iron excretion. Excess iron may be effectively removed by phlebotomy in hereditary hemochromatosis, but this method cannot be applied to chronic anemias associated with iron overload. In these diseases, iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Iron chelating therapy has changed the quality of life and life expectancy of thalassemic patients. However, the high cost and rigorous requirements of deferoxamine therapy, and the significant toxicity of deferiprone underline the need for the continued development of new and improved orally effective iron chelators. Such development, and the evolution of improved strategies of iron chelating therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant develop ments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload (Chapters 1-5).

EDTA chelation therapy removes from the human body, with relative safety and without surgery, metallic ions that play an important role in the formation of atherosclerotic plaque. Dr. Elmer Cranton's compilation of the most current and pertinent information on EDTA chelation therapy is now back in print, with even more information about chelation's effects, protocols, and status based on the latest research. Find out why more than a thousand physicians in the United States already offer EDTA chelation therapy as a safer and far less expensive alternative to surgical treatments for atherosclerosis.

Handbook of Arsenic Toxicology, Second Edition presents the latest findings on arsenic, including its chemistry, sources and effects on the environment and human health. The book discusses both acute and chronic effects, discussing many aspects of arsenic, from physical and chemical properties, exposure, epidemiology, organ toxicity, diagnosis, prevention and treatment. Fully updated and revised, this new edition includes new topics on risk assessment, molecular mechanisms of arsenic, advances in the integrated approach to testing, assessment and development, evaluation and application of high content predictive models, and new alternative methods (NAMS) in the context of Adverse Outcome Pathways (AOPs) to assess toxicology. This comprehensive resource allows readers to effectively assess the risks related to arsenic, providing them with all they need to know on arsenic exposure, toxicity and toxicity prevention. Brings together current findings on the effects of arsenic on the environment and human health Includes state-of-the-art techniques in arsenic toxicokinetics, speciation and molecular mechanisms Provides all the information needed for effective risk assessment, prevention and countermeasures

Within the last few years, iron research has yielded exciting new insights into the understanding of normal iron homeostasis. Such development, and the evolution of improved strategies of Iron Chelating Therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant developments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload. This volume highlights the impact of long term Iron Celating Therapy using deferoxamine or the new, but controversial oral iron chelator deferiprone based on experience gained by multicenter trails, with special emphasis on survival, morbidity and drug toxicity; it reviews the development of the new and improved orally effective chelators suitable for clinical use in the near future and examines novel strategies of iron chelating treatment for the control of cell proliferation in malignant disease or malaria.